Neurological Biomarkers Market – By Product Type, By Disease Type, By End Use, Global Forecast, 2025 to 2034

Neurological Biomarkers Market Size

The global neurological biomarkers market size was valued at USD 9.5 billion in 2024 and is estimated to grow at a CAGR of 10.9% from 2025 to 2034. In the past few years, there has been an increase in the number of people affected by neurological illnesses such as Alzheimer’s and Parkinson’s Disease. The elderly population tends to grow more, leading to the increased demand for personalized medicine. These changes progressively allow the market to grow.
 

Additionally, there has been an increase in the investment towards diagnosing and treating such primary health conditions, which has allowed the market for biomarkers to flourish. These proteins and genes associated with specific brain functions enhance the chances of early diagnosis. Later, these technologies can lead to improved diagnosis methods and results. For instance, the announcement made by Biogen, Beckman Coulter, and Fujirebio in July 2024 about their collaboration focused on developing and identifying blood-based biomarkers for tau pathology.
 

These developments could move clinical testing and marketing of the tau target AD biomarker test forward. Therefore, the effort of creating tau-specific blood biomarkers that reveal the amount of tau in patients can provide insight into the basic pathological changes that occur in AD and aids the development of new treatment drugs, which will enhance market growth.
 

Neurological biomarkers stand for biological features which are used to determine the existence, degree, or progress of neurological damage. These markers often take the form of molecules or genes and are found in the brain or blood, serving as indicators reflecting the neurological state of the individual. Biomarkers exist for Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, and even autism spectrum disorder.
 

Neurological Biomarkers Market Trends

The market for neurological biomarkers is currently facing several trends, including the increasing number of patients diagnosed with neurological conditions and rapid technological innovation.
 

• Development in biomedical technology has resulted in advanced diagnostic and therapeutic methods like genomic, proteomic, and imaging-based markers. These innovations assist quicker drug development, more sensitive detection, and non-invasive methods of testing.
   
• In addition, as precision medicine for older patients becomes increasingly common, the treatment for neurodegenerative conditions such as Alzheimer's, Parkinson's, and even multiple sclerosis is undergoing a significant change with the growing use of biomarkers.
   
• Disease-focused therapy through specific biomarker identification approaches is expected to change the treatment for several patients and there will be further growth in the market.
   

Neurological Biomarkers Market Analysis

Based on product type, the global market is divided into proteomic biomarkers, genomic biomarkers, metabolomic biomarkers, imaging, and other biomarker types. The proteomic biomarker segment dominated the market and was valued at USD 3.1 billion in 2024.
 

• There have been significant advancements in proteomics such as enhanced resolution and reproducibility of LC-MS/MS (liquid chromatography–mass spectrometry) and other instruments which, in turn, enabled better detection and quantification of biomarkers in neurological disorders.
   
• These steps assist in making diagnoses at early stages and improving treatment options for therapies such as Alzheimer's, which in turn, cost increases.
   
• Furthermore, the alter in dynamics to precision medicine in neurology will enhance the need for clinical diagnostics, which is anticipated to propel the need for proteomic biomarkers.

Based on disease type, the global neurological biomarkers market is categorized into Alzheimer’s disease, Parkinson’s disease, autism spectrum disorder, epilepsy and other diseases. The Alzheimer’s disease segment accounted for the highest market share of 45.5% in 2024.
 

• According to estimations in 2022 and 2023, almost 6.7 million Americans aged 65 and older will be inflicted with Alzheimer’s disease making it one of the most prevalent neurological diseases. The reason behind the boost in cases is driving demand for early diagnostic biomarkers which are significant for intervention and disease management.
   
• Also, the invention of blood-based biomarkers for Alzheimer’s has made diagnosis significantly easier and less expensive.
   
• With the rise in demand, companies like Quanterix and C2N Diagnostics have emerged, providing tests that are able to detect Tau protein, or Amyloid beta through blood instead of using the more complicated Cerebrospinal Fluid (CSF) tests, encouraging the expansion of the biomarkers market.
   

Based on end use, the neurological biomarkers market is categorized into hospitals and clinics, research laboratories, biopharmaceutical companies, and other end users. The hospitals and clinics segment dominated the market in 2024 and is anticipated to reach USD 11 billion by 2034.
 

• The sector that includes hospitals and clinics is incredibly impactful within the biomarker neurological market through the adoption of new diagnostic technologies that focus on the well-being of patients. Non-invasive treatment techniques are becoming more popular leading to earlier and more effective management of neurological conditions.
   
• For instance, treatment approaches are being designed to fit the individual patients of these centers that are utilizing biomarkers in forensic medicine. Government support, financing of key studies, and partnership with the private sector is aiding in the implementation of routine biomarker research and development activities within the clinical setting.
   
• The segment's penetration is being further pushed by regulatory campaigns directed to physicians and patients regarding the usefulness of biomarkers, which in turn contributes to the expansion of the market.

In 2024, the U.S. held a significant position in the North American neurological biomarkers market and was valued at USD 3.7 billion.
 

• Growth of the market in the U.S. is attributed to the increasing rates of disorders such as Alzheimer’s, Parkinson’s, multiple sclerosis, and autism spectrum disorders.
   
• Due to an increasing improvement of technologies used for biomarker development including digital biomarkers and AI-powered devices, it is anticipated that growth within the region will escalate.
   
• Additionally, increased focus on the treatment of a particular medical condition has resulted in the more frequent use of neurological biomarkers for precision medicine. With these, therapies can be more accurately tailored to genetic and other markers of the disease. This is especially important for treating neurodegenerative diseases where the effectiveness of treatment varies considerably among individuals.
   

Germany shows strong growth potential in the European neurological biomarkers market.
 

• Germany advanced its healthcare infrastructure and received significant government funding into the healthcare system greatly improved the growth metrics.
   
• Germany invests a lot of energy and resources into research development, especially neuroscience, greatly impacts the growth of biomarker-based diagnostics tools.
   
• Additionally, German research centers and pharmaceuticals are at the forefront in developing new biomarkers that target neurological conditions like Alzheimer’s and Parkinson’s, which further accelerates the market demand that aims for accurate diagnosis.
   

The neurological biomarkers market in Asia Pacific is estimated to grow at a CAGR of 11.4% over the next few years.
 

• The novel genomic, proteomic, and imaging markers have shown considerable promise to enhance the early neurological conditions’ diagnosis and tracking, in result, improving healthcare standards. Thus, these innovations are gaining momentum among Chinese hospitals and research institutes.
   
• In addition, the Chinese government is largely funding its healthcare and research sectors with proportions directed to improving the national capacity in tackling neurological conditions diagnosis and treatment.
   
• These changes prompted both local and foreign biopharmaceutical companies to build their research and development as well as production businesses in China.
   

Brazil's neurological biomarkers market is projected to witness growth in coming years.
 

• The healthcare market in Brazil is projected to see significant growth due to the improvement in the Healthcare infrastructure being promoted through government and private funding.
   
• Brazil has been active in the global advancements of proteomic, genomic, and imaging biomarkers which are increasingly relied upon for early detection of Alzheimer's disease. These biomarkers are known to significantly aid immunoassay methods on other diseases along with Alzheimer's and play an active role in contributing to the overall market growth of the country.
   

Saudi Arabia is anticipated to showcase significant growth in the Middle East and African market.
 

• As part of the Vision 2030 program, Saudi Arabia has been quick to implement modern advancements in its Healthcare sector. Alongside the advancements are investments towards the construction of diagnostic and research facilities that implement Neurological Biomarkers. There has also been an increase in the adoption of advanced diagnostic tools in research and academic hospitals of the country.
   
• There has also been an increase in the investment made by private healthcare practitioners and diagnostic providers towards using biomarkers. Private practitioners including laboratories and research centers are actively increasing their offerings towards tests of various neurological diseases which has led to an increased use of biomarkers.
   

Neurological Biomarkers Market Share

The market for neurological biomarkers corresponds with the activity of leading global pharmaceutical and biotechnology companies and regional participants, which brings competition at a global scale. Well-known neurological biomarkers are produced and marketed by leading brands in the pharmaceutical industry under different brand names. Businesses are also focusing on separating their offerings, gaining product approvals, and acquiring and partnering with other companies to become more competitive in the marketplace.
 

Neurological Biomarkers Market Companies

Few of the prominent players operating in the neurological biomarkers industry include:

• Abbott Laboratories
• ACOBIOM
• Alseres Pharmaceuticals
• Banyan Biomarkers
• Bio-Rad Laboratories
• DiaGenic ASA
• Johnson & Johnson Services
• Merck KGaA
• QIAGEN
• Quanterix
• Rules-Based Medicine
• Thermo Fisher Scientific 
   

USP For the Top Players:

• Comprehensive diagnostic solutions leveraging advanced biomarker detection technologies.
   
• Strong global presence with established infrastructure for neurological assays.
   
• Focus on integrating precision medicine with scalable testing platforms.
   
• Collaboration-driven innovation supporting multi-disciplinary research and clinical adoption.
   

Neurological Biomarkers Industry News

• In July 2023, Beckman Coulter Diagnostics, a clinical diagnostics leader, and Fujirebio, a leader in neurological markers and IVD manufacturing, announced a new partnership combining their respective immunoassay strengths to support therapeutic development, clinical trials, reimbursement, and routine clinical adoption in the field of neurodegenerative diseases.
   
• In July 2021, GlaxoSmithKline plc and Alector announced a strategic global collaboration for the development and commercialization of two clinical-stage, potential first-in-class monoclonal antibodies designed to elevate progranulin (PGRN) levels. This strategic collaboration helped the company expand its product offerings with new biomarker launches.
   

The neurological biomarkers market research report includes in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 – 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Product Type

• Proteomic biomarkers
• Genomic biomarkers
• Metabolomic biomarkers
• Imaging
• Other biomarker types

Market, By Disease Type

• Alzheimer’s disease
• Parkinson’s disease
• Autism spectrum disorders
• Epilepsy
• Other diseases

Market, By End Use

• Hospitals and clinics
• Research laboratories
• Biopharmaceutical companies
• Other end users

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea 
• Latin America
  • Brazil
  • Mexico
  • Argentina 
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE